Apart from mutations in EGFR, a significant proportion of NSCLC patients harbour somatic mutations in other oncogenes, downstream effector molecules of the EGFR pathway, including KRAS (15–25%), BRAF (1–3%) and NRAS (1%) [14, 15]. Here, EGFR is linked to non-small cell lung carcinoma.